IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. Email Format
Pharmaceutical ManufacturingNew Jersey, United States51-200 Employees
Mallinckrodt is a mid-sized global specialty biopharmaceutical and medical imaging company that develops, manufactures, markets and distributes specialty pharmaceutical products and imaging agents. Its portfolio targets autoimmune and rare diseases such as neurology, rheumatology, nephrology and pulmonology, alongside analgesics and central nervous system drugs prescribed by office- and hospital-based physicians. The company emphasizes capabilities in acquiring and managing regulated raw materials, regulatory expertise, and specialized chemistry, formulation and manufacturing. It organizes its operations into three segments: Specialty Brands, Specialty Generics, and Global Medical Imaging. It is based in Hampton, New Jersey, with a U.S. headquarters in St. Louis, Missouri, and maintains its principal executive office in Ireland. In 2025, Christiana Stamoulis was appointed President and Chief Financial Officer, effective September 22, 2025.